Canadian Medical Center’s H1 2022 net profit surges 60% to SAR 7.9 mln

Canadian Medical Center’s H1 2022 net profit surges 60% to SAR 7.9 mln

21/08/2022 Argaam Exclusive

View other reports

Canadian Medical Center Co. (CMCER) reported a net profit after Zakat and tax of SAR 7.9 million in H1 2022, an increase of 60% compared to nearly SAR 5 million in the prior-year period.



Financials (M)

Item 6m 2021 6m 2022 Change‬
Revenues 30.18 38.92 28.9 %
Gross Income 12.39 12.63 1.9 %
Operating Income 6.51 9.11 40.1 %
Net Income 4.96 7.94 59.9 %
Average Shares 77.00 77.00 -
EPS (Riyals) 0.06 0.10 59.9 %

The increase was mainly driven by higher operating revenue.



Current Half Annual Comparison (M)

Compared With The
Item H1 2021 H1 2022 Change‬
Revenues 30.18 38.92 28.9 %
Gross Income 12.39 12.63 1.9 %
Operating Income 6.51 9.11 40.1 %
Net Income 4.96 7.94 59.9 %
Average Shares 77.00 77.00 -
EPS (Riyals) 0.06 0.10 59.9 %

Total shareholders’ equity, excluding minority interest, stood at SAR 90.51 million as of June 30, 2022, compared to SAR 97 million in the year-earlier period.



Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
H1 2013 - - - - - -
H2 2013 - - - - - -
H1 2014 - - - - - -
H2 2014 - - - - - -
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 29.83 - 12.22 - 8.72 -
H2 2020 34.38 - 11.80 - 8.44 -
H1 2021 30.18 1.2 % 12.39 1.4 % 6.51 (25.4 %)
H2 2021 40.46 17.7 % 12.80 8.4 % 9.80 16.0 %
H1 2022 38.92 28.9 % 12.63 1.9 % 9.11 40.1 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
H1 2013 - - - - - -
H2 2013 - - - - - -
H1 2014 - - - - - -
H2 2014 - - - - - -
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 8.40 - 0.11 - 8.40 0.11
H2 2020 7.75 - 0.10 - 7.75 0.10
H1 2021 4.96 (40.9 %) 0.06 - 4.96 0.06
H2 2021 9.10 17.4 % 0.12 - 9.10 0.12
H1 2022 7.94 59.9 % 0.10 - 7.94 0.10

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
H1 2013 - - -
H2 2013 - - -
H1 2014 - - -
H2 2014 - - -
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 37.42 % 31.13 % 25.15 %
H1 2021 37.48 % 28.00 % 19.70 %
H2 2021 35.66 % 27.24 % 19.91 %
H1 2022 32.04 % 27.32 % 21.47 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
H1 2013 - - - -
H2 2013 - - - -
H1 2014 - - - -
H2 2014 - - - -
H1 2015 - - - -
H2 2015 - - - -
H1 2016 - - - -
H2 2016 - - - -
H1 2017 - - - -
H2 2017 - - - -
H1 2018 - - - -
H2 2018 - - - -
H1 2019 - - - -
H2 2019 - - - -
H1 2020 77.00 - - 0.19
H2 2020 77.00 0.21 0.21 1.20
H1 2021 77.00 0.17 0.17 1.26
H2 2021 77.00 0.18 0.18 1.23
H1 2022 77.00 0.22 0.22 1.18

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
H1 2013 - - -
H2 2013 - - -
H1 2014 - - -
H2 2014 - - -
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 47.36 47.36 7.05
H1 2022 22.96 22.96 4.32

Business Segments (Million)

Compared With The
Period Medical Clinics Sector Medical Clinics Project Contracts Sector


Share Price

Canadian Medical Center Co. (CMCER)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.